This randomized controlled trial compared the thrombolytic drugs tenecteplase and alteplase for the treatment of acute ischemic stroke. The trial assigned 75 patients in a 1:1:1 ratio to receive either alteplase (the standard treatment), tenecteplase at a dose of 0.1 mg/kg, or tenecteplase at a higher dose of 0.25 mg/kg. Patients were selected based on having a large perfusion lesion on CT imaging and an associated vessel occlusion. The primary outcomes were the extent of reperfusion on MRI and clinical improvement at 24 hours. The results showed that the tenecteplase groups had significantly greater reperfusion and clinical improvement compared to al